Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI recurrences. In both studies, adults with active CDI were randomized to receive blinded fidaxomicin 200 mg twice daily...

Full description

Saved in:
Bibliographic Details
Main Authors: Crook, Derrick W., Walker, A. Sarah, Kean, Yin, Weiss, Karl, Cornely, Oliver A., Miller, Mark A., Esposito, Roberto, Louie, Thomas J., Stoesser, Nicole E., Young, Bernadette C., Angus, Brian J., Gorbach, Sherwood L., Peto, Timothy E. A.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2012
Subjects:
Supplement Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3388031/
https://ncbi.nlm.nih.gov/pubmed/22752871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cis499
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items